• Je něco špatně v tomto záznamu ?

Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy

V. Kotrbová, B. Mrázová, M. Moserová, V. Martínek, P. Hodek, J. Hudeček, E. Frei, M. Stiborová,

. 2011 ; 82 (6) : 669-80. [pub] 20110613

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12028239

Ellipticine is a pro-drug, whose activation is dependent on its oxidation by cytochromes P450 (CYP) and peroxidases. Cytochrome b(5) alters the ratio of ellipticine metabolites formed by isolated reconstituted CYP1A1 and 1A2, favoring formation of 12-hydroxy- and 13-hydroxyellipticine metabolites implicated in ellipticine-DNA adduct formation, at the expense of 9-hydroxy- and 7-hydroxyellipticine that are detoxication products. Cytochrome b(5) enhances the production of 12-hydroxy and 13-hydroxyellipticine. The change in metabolite ratio results in an increased formation of covalent ellipticine-DNA adducts, one of the DNA-damaging mechanisms of ellipticine antitumor action. This finding explains previous apparent discrepancies found with isolated enzymes and in vivo, where CYP1A enzymatic activation correlated with ellipticine-DNA-adduct levels while isolated CYP1A1 or 1A2 in reconstituted systems were much less effective than CYP3A4. The effect of cytochrome b(5) might be even more pronounced in vivo, since, as we show here, ellipticine increases levels of cytochrome b(5) in rat liver. Our results demonstrate that both the native 3D structure of cytochrome b(5) and the presence of the heme as an electron transfer agent in this protein enable a shift in ellipticine metabolites formed by CYP1A1/2.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12028239
003      
CZ-PrNML
005      
20121206114304.0
007      
ta
008      
120817e20110613enk f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.bcp.2011.06.003 $2 doi
035    __
$a (PubMed)21683692
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kotrbová, Věra $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic.
245    10
$a Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy / $c V. Kotrbová, B. Mrázová, M. Moserová, V. Martínek, P. Hodek, J. Hudeček, E. Frei, M. Stiborová,
520    9_
$a Ellipticine is a pro-drug, whose activation is dependent on its oxidation by cytochromes P450 (CYP) and peroxidases. Cytochrome b(5) alters the ratio of ellipticine metabolites formed by isolated reconstituted CYP1A1 and 1A2, favoring formation of 12-hydroxy- and 13-hydroxyellipticine metabolites implicated in ellipticine-DNA adduct formation, at the expense of 9-hydroxy- and 7-hydroxyellipticine that are detoxication products. Cytochrome b(5) enhances the production of 12-hydroxy and 13-hydroxyellipticine. The change in metabolite ratio results in an increased formation of covalent ellipticine-DNA adducts, one of the DNA-damaging mechanisms of ellipticine antitumor action. This finding explains previous apparent discrepancies found with isolated enzymes and in vivo, where CYP1A enzymatic activation correlated with ellipticine-DNA-adduct levels while isolated CYP1A1 or 1A2 in reconstituted systems were much less effective than CYP3A4. The effect of cytochrome b(5) might be even more pronounced in vivo, since, as we show here, ellipticine increases levels of cytochrome b(5) in rat liver. Our results demonstrate that both the native 3D structure of cytochrome b(5) and the presence of the heme as an electron transfer agent in this protein enable a shift in ellipticine metabolites formed by CYP1A1/2.
650    _2
$a zvířata $7 D000818
650    _2
$a antitumorózní látky fytogenní $x chemie $x metabolismus $x farmakologie $7 D000972
650    _2
$a transportní proteiny $x metabolismus $7 D002352
650    _2
$a cytochrom P-450 CYP1A1 $x metabolismus $7 D019363
650    _2
$a cytochromy $x metabolismus $7 D003580
650    _2
$a adukty DNA $x metabolismus $7 D018736
650    _2
$a elipticiny $x chemie $x metabolismus $x farmakologie $7 D004611
650    _2
$a hemoproteiny $x metabolismus $7 D006420
650    _2
$a injekce intraperitoneální $7 D007274
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metabolická inaktivace $7 D008658
650    _2
$a jaterní mikrozomy $x účinky léků $x enzymologie $x metabolismus $7 D008862
650    _2
$a oxidace-redukce $7 D010084
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mrázová, Barbora
700    1_
$a Moserová, Michaela
700    1_
$a Martínek, Václav
700    1_
$a Hodek, Petr
700    1_
$a Hudeček, Jiří
700    1_
$a Frei, Eva
700    1_
$a Stiborová, Marie
773    0_
$w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 82, č. 6 (20110613), s. 669-80
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21683692 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121206114337 $b ABA008
999    __
$a ok $b bmc $g 950281 $s 785585
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 82 $c 6 $d 669-80 $e 20110613 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
LZP    __
$a Pubmed-20120817/11/04

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...